27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the US spends more per capita on prescription medicines than any other country. 

This is not just down to the volume of medication consumed, but also the cost for each, which is often notoriously high. Over the summer the Trump administration made multiple announcements around its plans to lower costs, and yet even with these changes, just a few months on, prices have in fact climbed.

So is there another answer, a system which offers transparency on costs due to set of clear rules and that can be fair to payer, patient and manufacturer alike? With this in mind Leela Barham takes a look at the use of value-based payment models in the US.

Read Pharmaphorum article